The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in ...

Amneal Pharmaceuticals (AMRX) announced that three large insurance coverage accounts, the Veterans Administration, UnitedHealthcare (UNH) and ...

Menopause-related health problems, both physical and mental, have become a pressing issue for women at the transformative age ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

Osvyrti ®– Bone / Osteoporosis (60mg Pre-Filled Syringe) Jubereq ®– Oncology (120mg Vial) Joe Dunford, Accord's Vice ...

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

Integrum AB (publ) today announces that the company has implemented a new compensation package for its Board Director and Acting CEO Scott Flora. "Integrum is currently undergoing a major strategic ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...